Patents by Inventor Sherry Voytik
Sherry Voytik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230068180Abstract: A collagen-based therapeutic delivery device includes an insoluble synthetic collagen-fibril matrix comprising a polymerization product of soluble oligomeric collagen or a polymerization product of a mixture of soluble oligomeric collagen with one or more type of non-oligomeric soluble collagen molecules, such as, for example, soluble telocollagen and/or soluble atelocollagen, and an active agent dispersed throughout the collagen-fibril matrix or within a portion of the collagen-fibril matrix. A pre-mat rix composition includes an aqueous solution including soluble collagen-fibril building blocks and an active agent in the aqueous solution. The soluble collagen-fibril building blocks include soluble oligomeric collagen or a mixture of soluble oligomeric collagen with non-oligomeric soluble collagen molecules. The building blocks are operable to self-assemble into a macromolecular synthetic collagen-fibril matrix in the absence of an exogenous cross-linking agent.Type: ApplicationFiled: June 30, 2022Publication date: March 2, 2023Inventors: Sherry Voytik-Harbin, Rucha Joshi
-
Patent number: 10828337Abstract: Materials and methods are disclosed for controlling vasculogenesis using building blocks of a collagen matrix and endothelial colony forming cells (ECFC). The building blocks may be isolated by fractionating an acid soluble Type I collagen. The building blocks comprising monomers and/or oligomers may be recombined in desired ratios to alter the matrix microenvironment and to influence ECFC behavior.Type: GrantFiled: February 7, 2018Date of Patent: November 10, 2020Assignee: Indiana University Research and Technology CorporationInventors: Mervin C. Yoder, Paul Critser, Sherry Voytik-Harbin
-
Publication number: 20190351097Abstract: A collagen-based therapeutic delivery device includes an insoluble synthetic collagen-fibril matrix comprising a polymerization product of soluble oligomeric collagen or a polymerization product of a mixture of soluble oligomeric collagen with one or more type of non-oligomeric soluble collagen molecules, such as, for example, soluble telocollagen and/or soluble atelocollagen, and an active agent dispersed throughout the collagen-fibril matrix or within a portion of the collagen-fibril matrix. A pre-matrix composition includes an aqueous solution including soluble collagen-fibril building blocks and an active agent in the aqueous solution. The soluble collagen-fibril building blocks include soluble oligomeric collagen or a mixture of soluble oligomeric collagen with non-oligomeric soluble collagen molecules. The building blocks are operable to self-assemble into a macromolecular synthetic collagen-fibril matrix in the absence of an exogenous cross-linking agent.Type: ApplicationFiled: June 10, 2019Publication date: November 21, 2019Applicant: Purdue Research FoundationInventor: Sherry Voytik-Harbin
-
Patent number: 10314940Abstract: A collagen-based therapeutic delivery device includes an insoluble synthetic collagen-fibril matrix comprising a polymerization product of soluble oligomeric collagen or a polymerization product of a mixture of soluble oligomeric collagen with one or more type of non-oligomeric soluble collagen molecules, such as, for example, soluble telocollagen and/or soluble atelocollagen, and an active agent dispersed throughout the collagen-fibril matrix or within a portion of the collagen-fibril matrix. A pre-matrix composition includes an aqueous solution including soluble collagen-fibril building blocks and an active agent in the aqueous solution. The soluble collagen-fibril building blocks include soluble oligomeric collagen or a mixture of soluble oligomeric collagen with non-oligomeric soluble collagen molecules. The building blocks are operable to self-assemble into a macromolecular synthetic collagen-fibril matrix in the absence of an exogenous cross-linking agent.Type: GrantFiled: August 27, 2015Date of Patent: June 11, 2019Assignee: Purdue Research FoundationInventor: Sherry Voytik-Harbin
-
Publication number: 20190000891Abstract: Materials and methods are disclosed for controlling vasculogenesis using building blocks of a collagen matrix and endothelial colony forming cells (ECFC). The building blocks may be isolated by fractionating an acid soluble Type I collagen. The building blocks comprising monomers and/or oligomers may be recombined in desired ratios to alter the matrix microenvironment and to influence ECFC behavior.Type: ApplicationFiled: February 7, 2018Publication date: January 3, 2019Inventors: Mervin C. Yoder, Paul Critser, Sherry Voytik-Harbin
-
Publication number: 20170274120Abstract: A collagen-based therapeutic delivery device includes an insoluble synthetic collagen-fibril matrix comprising a polymerization product of soluble oligomeric collagen or a polymerization product of a mixture of soluble oligomeric collagen with one or more type of non-oligomeric soluble collagen molecules, such as, for example, soluble telocollagen and/or soluble atelocollagen, and an active agent dispersed throughout the collagen-fibril matrix or within a portion of the collagen-fibril matrix. A pre-matrix composition includes an aqueous solution including soluble collagen-fibril building blocks and an active agent in the aqueous solution. The soluble collagen-fibril building blocks include soluble oligomeric collagen or a mixture of soluble oligomeric collagen with non-oligomeric soluble collagen molecules. The building blocks are operable to self-assemble into a macromolecular synthetic collagen-fibril matrix in the absence of an exogenous cross-linking agent.Type: ApplicationFiled: August 27, 2015Publication date: September 28, 2017Inventor: Sherry Voytik-Harbin
-
Publication number: 20150105323Abstract: The present disclosure provides an engineered collagen composition comprising collagen, wherein the collagen composition is compressed to form a gradient of at least one physical property. Methods of using and of manufacturing the engineered collagen compositions of the present disclosure are also provided.Type: ApplicationFiled: October 16, 2014Publication date: April 16, 2015Inventors: Tyler NOVAK, Kevin BLUM, Corey NEU, Sherry VOYTIK-HARBIN
-
Publication number: 20140193473Abstract: Materials and methods are disclosed for controlling vasculogenesis using building blocks of a collagen matrix and endothelial colony forming cells (ECFC). The building blocks may be isolated by fractionating an acid soluble Type I collagen. The building blocks comprising monomers and/or oligomers may be recombined in desired ratios to alter the matrix microenvironment and to influence ECFC behavior.Type: ApplicationFiled: June 6, 2012Publication date: July 10, 2014Applicant: Indiana University Research and Technology Corp.Inventors: Mervin C. Yoder, Paul Critser, Sherry Voytik-Harbin
-
Patent number: 8741352Abstract: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.Type: GrantFiled: September 7, 2007Date of Patent: June 3, 2014Assignee: Cook Biotech IncorporatedInventors: Jason P. Hodde, David M. J. Ernst, Lal Ninan, Sherry Voytik-Harbin, Nathan Hammond
-
Publication number: 20110165126Abstract: An improved tissue graft construct comprising submucosa of a warm-blooded vertebrate and a preselected group of eukaryotic cells are described. The improved tissue graft constructs can be used in accordance with the present invention to enhance the repair of damaged or diseased tissues in vivo.Type: ApplicationFiled: August 9, 2010Publication date: July 7, 2011Applicants: Purdue Research Foundation, Clarian Health Partners, Inc.Inventors: Stephen F. Badylak, Kristina Lindberg, George B. Boder, Sherry Voytik-Harbin
-
Patent number: 7820634Abstract: A composition useful for the production of transformed eukaryotic cells is described. The composition comprises submucosal tissue and a nucleic acid sequence. The nucleic acid sequence is typically recombinant DNA including gene(s) encoding for one or more biofunctional proteins. The submucosal tissue component of the present composition comprises the tunica submucosa of vertebrate intestine delaminated from the tunica muscularis and at least the luminal portion of the tunica mucosa. Injection or implantation of the composition into a host induces the formation of transformed cells capable of expressing gene(s) encoded by the nucleic acid sequence.Type: GrantFiled: May 2, 2007Date of Patent: October 26, 2010Assignees: Purdue Research Foundation, The Regents of the University of Michigan, Clarian Health Partners, Inc.Inventors: Stephen F. Badylak, Jeffrey Bonadio, Sherry Voytik
-
Patent number: 7771717Abstract: An improved tissue graft construct comprising submucosa of a warm-blooded vertebrate and a preselected group of eukaryotic cells are described. The improved tissue graft constructs can be used in accordance with the present invention to enhance the repair of damaged or diseased tissues in vivo.Type: GrantFiled: February 13, 2007Date of Patent: August 10, 2010Assignees: Purdue Research Foundation, Clarian Health Partners, Inc.Inventors: Stephen F. Badylak, Khristina Lindberg, George B. Boder, Sherry Voytik-Harbin
-
Publication number: 20080107750Abstract: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.Type: ApplicationFiled: September 7, 2007Publication date: May 8, 2008Inventors: Jason Hodde, David Ernst, Lal Ninan, Sherry Voytik-Harbin, Nathan Hammond
-
Publication number: 20070202599Abstract: A composition useful for the production of transformed eukaryotic cells is described. The composition comprises submucosal tissue and a nucleic acid sequence. The nucleic acid sequence is typically recombinant DNA including gene(s) encoding for one or more biofunctional proteins. The submucosal tissue component of the present composition comprises the tunica submucosa of vertebrate intestine delaminated from the tunica muscularis and at least the luminal portion of the tunica mucosa. Injection or implantation of the composition into a host induces the formation of transformed cells capable of expressing gene(s) encoded by the nucleic acid sequence.Type: ApplicationFiled: May 2, 2007Publication date: August 30, 2007Inventors: Stephen Badylak, Jeffrey Bonadio, Sherry Voytik
-
Publication number: 20070141037Abstract: An improved tissue graft construct comprising submucosa of a warm-blooded vertebrate and a preselected group of eukaryotic cells are described. The improved tissue graft constructs can be used in accordance with the present invention to enhance the repair of damaged or diseased tissues in vivo.Type: ApplicationFiled: February 13, 2007Publication date: June 21, 2007Inventors: Stephen Badylak, Khristina Lindberg, George Boder, Sherry Voytik-Harbin
-
Patent number: 7175841Abstract: An improved tissue graft construct comprising submucosa of a warm-blooded vertebrate and a preselected group of eukaryotic cells are described. The improved tissue graft constructs can be used in accordance with the present invention to enhance the repair of damaged or diseased tissues in vivo.Type: GrantFiled: October 17, 2002Date of Patent: February 13, 2007Assignee: Purdue Research FoundationInventors: Stephen F Badylak, Christina Lindberg, George B. Boder, Sherry Voytik-Harbin
-
Publication number: 20050003537Abstract: A composition useful for the production of transformed eukaryotic cells is described. The composition comprises submucosal tissue and a nucleic acid sequence. The nucleic acid sequence is typically recombinant DNA including gene(s) encoding for one or more biofunctional proteins. The submucosal tissue component of the present composition comprises the tunica submucosa of vertebrate intestine delaminated from the tunica muscularis and at least the luminal portion of the tunica mucosa. Injection or implantation of the composition into a host induces the formation of transformed cells capable of expressing gene(s) encoded by the nucleic acid sequence.Type: ApplicationFiled: November 24, 2003Publication date: January 6, 2005Inventors: Stephen Badylak, Jeffrey Bonadio, Sherry Voytik
-
Patent number: 6653291Abstract: A composition useful for the production of transformed eukaryotic cells is described. The composition comprises submucosal tissue and a nucleic acid sequence. The nucleic acid sequence is typically recombinant DNA including gene(s) encoding for one or more biofunctional proteins. Injection or implantation of the composition into a host induces the formation of transformed cells capable of expressing gene(s) encoded by the nucleic acid sequence.Type: GrantFiled: February 17, 1995Date of Patent: November 25, 2003Assignees: Purdue Research Foundation, The Regents of the University of MichiganInventors: Stephen F. Badylak, Jeffrey Bonadio, Sherry Voytik
-
Publication number: 20030064056Abstract: An improved tissue graft construct comprising submucosa of a warm-blooded vertebrate and a preselected group of eukaryotic cells are described. The improved tissue graft constructs can be used in accordance with the present invention to enhance the repair of damaged or diseased tissues in vivo.Type: ApplicationFiled: October 17, 2002Publication date: April 3, 2003Inventors: Stephen F. Badylak, Kristina Lindberg, George B. Boder, Sherry Voytik-Harbin
-
Patent number: 6485723Abstract: An improved tissue graft construct comprising submucosa of a warm-blooded vertebrate and a preselected group of eukaryotic cells are described. The improved tissue graft constructs can be used in accordance with the present invention to enhance the repair of damaged or diseased tissues in vivo.Type: GrantFiled: May 8, 2000Date of Patent: November 26, 2002Assignee: Purdue Research FoundationInventors: Stephen F. Badylak, Christina Lindberg, George B. Boder, Sherry Voytik-Harbin